Biography
Janusz Dutkowski is Co-founder and CEO of Data4Cure, Inc. – a company focused on combining systems biology, machine learning and AI to facilitate continuous translation of biomedical data to knowledge. His background is in mathematics and computer science. For the last 15 years he has been working at the intersection of mathematics, computer science and biology to develop new data-driven technologies to advance the discovery of new biomarkers and precision-based therapies. Before founding Data4Cure he was a scientist at the University of California, San Diego where along with Dr. Trey Ideker he led the development of methods for multiscale analysis of molecular networks and integrative methods for biomarker discovery from multidimensional data. He has co-authored over 20 research papers published in scientific journals including Nature Biotechnology, Science and Cell.

Biography
Dr. Sachdev, Director of Oncology Biomarker Research at Eisai, a human health care (hhc) company, supports the clinical development of a diverse in-house pipeline of oncology compounds. During her time at Eisai, Dr. Sachdev has increasingly focused on cross-functional and global coordination of biomarker research activities to support the development of targeted therapeutics by alignment of drug and diagnostic strategies to achieve the oncology pipeline clinical objectives. Previously, Dr. Sachdev was a scientist at The Rockefeller University focusing on stem cell biology, cancer signaling networks and systems biology. Dr. Sachdev received her B.S. from Cornell University, her Ph.D. in Biochemistry and Molecular Biology from Mount Sinai-New York University School of Medicine. She has co-authored numerous research publications in the fields of cancer signaling networks, cancer genomics and personalized medicine and presented at international scientific conferences.

Biography
Paul leads Oncology Translational Research at Pfizer with responsibility for Translational Pharmacology, Tumor Morphology, Clinical Research Lab, Translational Leads and Biomarker Assay Specialists in early clinical development as well as Computational Biology spanning research through late development. Paul joined Agouron Pharmaceuticals (now Pfizer) in 1994 as a computational chemist to build innovative tools for structure-enabled drug discovery, then supported projects in Oncology, Virology and CNS from 1998-2001. From 2001-2005, Paul formed a Bioinformatics Group and co-led Molecular Design, helped create the La Jolla Obesity & Diabetes organization while leading a drug discovery team to nominate threes clinical candidates. Starting in 2005, Paul built the Oncology Computational Biology group and led an interdisciplinary group of scientists focused on Oncology Pathways prior to assuming the role as Head of Translational Research in 2013.